Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
The current Vertex Pharmaceuticals(VRTX) stock price is $477.10, with a market capitalization of 121.03B. The stock trades at a price-to-earnings (P/E) ratio of 28.65.
During the trading session on 2026-08-01, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $480.67 and a low of $469.87. At a current price of $477.10, the stock is +1.5% higher than the low and still -0.7% under the high.
Trading activity shows a volume of 918.79K, compared to an average daily volume of 1.3M.
The stock's 52-week range extends from a low of $362.50 to a high of $533.67.
The stock's 52-week range extends from a low of $362.50 to a high of $533.67.
VRTX News
In July 2026, AbCellera Biologics announced a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cel...
Advertisement Vertex Pharmaceuticals stock reaction to new AbCellera collaboration Vertex Pharmaceuticals (VRTX) drew fresh attention after AbCellera Biologic...
AbCellera (ABCL) announced a collaboration with Vertex Pharmaceuticals Incorporated (VRTX) to research, develop, manufacture, and commercialize multispecific T-...
Analyst ratings
78%
of 32 ratingsMore VRTX News
Vertex Pharmaceuticals stock has delivered a strong 5 year return of 145.1%. However, the current checks send a mixed message, with a Discounted Cash Flow (DCF)...
The second-quarter 2024 reporting cycle of the Medical sector will gain further traction this week. The sector mainly comprises pharma/biotech and medical devic...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.